Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | G6PD | P11413 | 2/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | TDP2 | O95551 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | ALDH1A2 | O94788 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30103172 | 1.00 | PIK3CD (0.38) | PIK3CDG6PDPI4KAPIK3CGTDP2 | |
| SCHEMBL24111058 | 0.91 | LMNA (0.38) | PIK3CDKDM1A | |
| SCHEMBL30103301 | 0.91 | LMNA (0.38) | PIK3CDKDM1A | |
| SCHEMBL30103175 | 0.89 | PDE4D (0.41) | PI4KAPIK3CGALDH1A1 | |
| SCHEMBL24110812 | 0.89 | PDE4D (0.41) | PI4KAPIK3CGALDH1A1 | |
| SCHEMBL23958242 | 0.87 | TDO2 (0.45) | PIK3CDPI4KAPIK3CGALDH1A2ALDH1A1 | |
| SCHEMBL30025705 | 0.87 | TDO2 (0.45) | PIK3CDPI4KAPIK3CGALDH1A2ALDH1A1 | |
| SCHEMBL24110797 | 0.86 | ABCG2 (0.42) | PIK3CDG6PDPI4KAPIK3CG | |
| SCHEMBL30103185 | 0.86 | ABCG2 (0.42) | PIK3CDG6PDPI4KAPIK3CG | |
| SCHEMBL24111051 | 0.82 | HTR7 (0.41) | G6PDALDH1A2ALDH1A1ALDH1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115427399-A | 2-heteroarylaminoquinazolinone derivatives | 住友制药株式会社 | 2022-12-02 | — | — | CN | claimed |
| CN-115427399-A | 2-heteroarylaminoquinazolinone derivatives | 住友制药株式会社 | 2022-12-02 | — | — | CN | disclosed |
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-16 | — | — | US | disclosed |
| WO-2021215537-A1 | 2-HETEROARYLAMINOQUINAZOLINONE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387967-A1 | 2-HETEROARYL AMINOQUINAZOLINONE DERIVATIVE | CRKL, CLIC4, CLIC1 | PIK3CD 3088/4885G6PD 1971/4885PI4KA 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.